Systemic lupus erythematosus: Difference between revisions
From IDWiki
m (Text replacement - "== Clinical Presentation" to "== Clinical Manifestations") |
(→) |
||
Line 1: | Line 1: | ||
== |
==Definition== |
||
* |
*Multisystem inflammatory disorder of unknown etiology |
||
== |
==ACR Classification Criteria== |
||
4 or more of the following (4RASHES mnemonic) |
4 or more of the following (4RASHES mnemonic) |
||
* |
*Four dermatologic manifestations |
||
** |
**Malar rash: spares nasolabial folds |
||
** |
**Discoid rash: erythemaous plaques/patches |
||
** |
**Photosensitivity: rash, not sunburn |
||
** |
**Mucocutaneous ulcers: oropharynx or nasopharynx, often painless |
||
* |
*Renal disorder |
||
** |
**Proteinuria >0.5g/d or 3+ |
||
** |
**Any cellular or granular casts |
||
* |
*Arthritis: non-erosive involving 2 or more joints |
||
* |
*Serositis: pleuritis or pericarditis |
||
* |
*Hematologic disorder |
||
** |
**Hemolytic anemia |
||
** |
**Leukopenia |
||
** |
**Lymphopenia: most important |
||
** |
**Thrombocytopenia |
||
* |
*Neurological excitability |
||
** |
**Seizures |
||
** |
**Psychosis |
||
* |
*Serology (non-ANA) |
||
** |
**Anti-dsDNA antibodies |
||
** |
**Anti-Sm antibodies |
||
** |
**Anti-phospholipid antibodies |
||
* |
*Serology (ANA): most sensitive finding (~98%) |
||
== |
==Clinical Manifestations== |
||
* |
*See above criteria |
||
* |
*Fevers and other constitutional symptoms |
||
* |
*Any other non-specific rash, even if not in criteria |
||
** |
**Discoid rash forms scars |
||
* |
*Alopecia, either discrete or global |
||
== |
==Investigations== |
||
* |
*Most important tests |
||
** |
**CBC for lymphopenia & other hematologic abnormalities |
||
** |
**Urinalysis for active sediment |
||
* |
*Serology |
||
** |
**ANA most sensitive, anti-Smith and anti-dsDNA are most specific |
||
** |
**APLA |
||
** |
**Can be either seroconcordant or -discordant for dsDNA, C3/C4, ESR/CRP during flares |
||
== |
==Management== |
||
=== |
===Acute=== |
||
* |
*[[Prednisone]] 0.5-1 mg/kg depending on severity |
||
* |
*[[Cyclophosphamide]] if severe or renal involvement |
||
* |
**vs. [[MMF]] |
||
=== |
===Chronic=== |
||
* |
*[[Hydroxychloroquine]] |
||
** |
**Load with 400-600 mg TDD split BID for 1-3 months |
||
** |
**Step down to 6.75 mg/kg maintenance |
||
** |
**Needs Ophthalmology follow-up for rare macular side effect |
||
** |
**Best for skin |
||
* |
*[[Azathioprine]] as steroid-sparing agent |
||
[[Category:Rheumatology]] |
[[Category:Rheumatology]] |
Latest revision as of 02:17, 3 August 2020
Definition
- Multisystem inflammatory disorder of unknown etiology
ACR Classification Criteria
4 or more of the following (4RASHES mnemonic)
- Four dermatologic manifestations
- Malar rash: spares nasolabial folds
- Discoid rash: erythemaous plaques/patches
- Photosensitivity: rash, not sunburn
- Mucocutaneous ulcers: oropharynx or nasopharynx, often painless
- Renal disorder
- Proteinuria >0.5g/d or 3+
- Any cellular or granular casts
- Arthritis: non-erosive involving 2 or more joints
- Serositis: pleuritis or pericarditis
- Hematologic disorder
- Hemolytic anemia
- Leukopenia
- Lymphopenia: most important
- Thrombocytopenia
- Neurological excitability
- Seizures
- Psychosis
- Serology (non-ANA)
- Anti-dsDNA antibodies
- Anti-Sm antibodies
- Anti-phospholipid antibodies
- Serology (ANA): most sensitive finding (~98%)
Clinical Manifestations
- See above criteria
- Fevers and other constitutional symptoms
- Any other non-specific rash, even if not in criteria
- Discoid rash forms scars
- Alopecia, either discrete or global
Investigations
- Most important tests
- CBC for lymphopenia & other hematologic abnormalities
- Urinalysis for active sediment
- Serology
- ANA most sensitive, anti-Smith and anti-dsDNA are most specific
- APLA
- Can be either seroconcordant or -discordant for dsDNA, C3/C4, ESR/CRP during flares
Management
Acute
- Prednisone 0.5-1 mg/kg depending on severity
- Cyclophosphamide if severe or renal involvement
- vs. MMF
Chronic
- Hydroxychloroquine
- Load with 400-600 mg TDD split BID for 1-3 months
- Step down to 6.75 mg/kg maintenance
- Needs Ophthalmology follow-up for rare macular side effect
- Best for skin
- Azathioprine as steroid-sparing agent